Finerenone

Where the papers sit

16 papers from the last 6 months study finerenone directly · updated from PubMed 12 Oct 2026

• Kidney Protection in CKD

  Finerenone is being tested across diabetic and non-diabetic CKD, including IgA nephropathy, with eGFR and proteinuria as recurring endpoints. Real-world studies are moving toward practical use alongside SGLT2 inhibitors and in patients with preserved kidney function. Hyperkalemia and serum potassium remain the main safety constraints, while ischemic stroke and long-term kidney outcomes are also being assessed. Mechanistic work extends the focus to fibrosis, including peritoneal fibrosis and restored autophagy flux.

  9 papers · 56.2%

• Mineralocorticoid Blockade in Heart Failure

  Mineralocorticoid receptor blockade is moving into heart failure with mildly reduced or preserved ejection fraction, where finerenone is being compared with spironolactone. SGLT2 inhibitor use, transportability of trial effects, and 12-month clinical events frame the main clinical questions. The evidence remains largely comparative and observational rather than definitive for superiority. Prescription patterns suggest broader cardiovascular-kidney use, but optimal patient selection and outcomes remain open.

  5 papers · 31.2%

• Cardiac Microvascular Injury

  Diabetic cardiomyopathy is being linked to cardiac microvascular injury, endothelial-cell damage, and neutrophil extracellular trap formation. Finerenone is being evaluated preclinically for improving cardiac dysfunction while modulating AKT-related signaling and damage-associated molecular patterns. The evidence is early and comes mainly from animal models, so effects on clinical heart failure endpoints remain unknown. A separate bosentan combination study broadens the work toward pharmacologic protection from cardiac dysfunction.

  2 papers · 12.5%